UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...

Okanagan Clinical Trials is offering new opportunities for people to participate in important clinical research studies ...

Early-onset Alzheimer's, affecting individuals under 65, presents unique challenges with memory, thinking, and daily ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

The model reveals that more connected brain regions are more prone to damage, while isolated areas remain resilient. This approach offers a powerful framework for understanding disease progression and ...

Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the Alzheimer's Association International Conference (AAIC), ...

Lexington, Massachusetts Tuesday, July 22, 2025, 18:00 Hrs [IST] ...

Researchers are investigating blood-based biomarkers like pTau217 for Alzheimer’s detection, offering a less invasive ...

Roche has obtained European approval for a blood test to help rule out Alzheimer’s disease, allowing patients to avoid ...

Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, both in the development of disease modifying therapies (DMTs) and ...

A multi-centre, prospective trial involving 787 subjects across Australia, Europe, and the US formed the basis for the CE ...

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid ...